4/A: Cardio Diagnostics CEO Meeshanthini Dogan Acquires Additional Shares
SEC Form 4/A
Cardio Diagnostics CEO Meeshanthini Dogan reports the acquisition of 68,965 shares of common stock at $0.29 per share.
Summary
- Meeshanthini Dogan, CEO of Cardio Diagnostics Holdings, Inc., filed an amended Form 4 on October 8, 2024, reporting a transaction from September 6, 2024.
- The report details the acquisition of 68,965 shares of common stock at a price of $0.29 per share.
- Following the transaction, Dogan beneficially owns 1,655,429 shares of common stock.
- The shares are held both individually and jointly with her spouse, who is the issuer's Chief Technology Officer, as joint tenants with rights of survivorship.
- Of the total shares, 1,586,464 are held individually, and 68,965 are held jointly.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition. The CEO's purchase could be seen as a positive signal, but it's not definitively bullish.
Positives
- The CEO's purchase of additional shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.
Stakeholder Impact
- The stock acquisition by the CEO could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of transaction: Acquisition of common stock. |
| 10/07/2024 | Date of original filing of Form 4 (amended). |
| 10/08/2024 | Date of amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.